천연형 인 적혈구 조혈인자의 변이원성시험

Mutagenicity Study of Recombinant Human Erythropoietin(rhEPO)

  • 강경구 (동아제약(주)연구소) ;
  • 조현 (동아제약(주)연구소) ;
  • 김동환 (동아제약(주)연구소) ;
  • 백남기 (동아제약(주)연구소) ;
  • 김원배 (동아제약(주)연구소)
  • Kang, Kyung-Koo (Research Laboratories, Dong-A Pharmaceutical Co. Ltd.) ;
  • Cho, Hyeon (Research Laboratories, Dong-A Pharmaceutical Co. Ltd.) ;
  • Kim, Dong-Hwan (Research Laboratories, Dong-A Pharmaceutical Co. Ltd.) ;
  • Baik, Nam-Gi (Research Laboratories, Dong-A Pharmaceutical Co. Ltd.) ;
  • Kim, Won-Bae (Research Laboratories, Dong-A Pharmaceutical Co. Ltd.)
  • 발행 : 1998.03.01

초록

Mutagenicity of recombinant human erythropoietin (rhEPO) was examined in the reverse mutation test on bacteria, in the chromosomal aberration test on cultured mammalian cells and in the micronucleus test on mice. The reverse mutation test was performed by a plate incorporation method with or wothout a metabolic activation system (59 Mix) using Salmonella typhimurium strain TA100, TA1535, TA98 and TA 1537. The rhEPO did not significantly increase revertant colonies in any of the test strains under any conditions at dose levels ranging from 1000 H/ml to 62.5 lu/plate, compared with the vehicle control. In the chromosomal aberration test using cultured Chinese Hamster Lung (CHL) cells, the number of aberrant cells was not increased in the presence or absence of 59 Mix at concentrations of 1000 lU/ml to 250 lU/ml, compared with the vehicle control. In the micronucleus test, male ICR mice were given rhEPO intraperitoneally at a dose level of 25000, 12500 and 6250 lU/kg. The incidence of bone marrow micronucleated polychromatic erythrocytes was not different from that of the vehicle control. From these results, rhEPO is considered to be non-mutagenic under the present test conditions.

키워드